ASXL2

Across TCGA pan-cancer cohorts, ASXL2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ASXL2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ASXL2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ASXL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ASXL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.975	0.633	<.001	25	view →
PDAC	DFS	Tertile	All	0.297	0.509	.006	22	view →
HNSC	OS	Tertile	II,III,IV	0.791	0.940	.022	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ASXL2–CCRCC (OS)

Open the CCRCC breakdown →